News | Breast Imaging | March 18, 2021

According to AJR, contrast-enhanced mammography showed concordance with MRI in women with newly diagnosed breast cancer and breast augmentation

Left to right: Subtraction right mediolateral oblique (MLO) CEM was non-diagnostic because of artifact, potentially due to motion misregistration from extended exposure time; subtraction right MLO implant displaced CEM image shows 5.8 cm enhancing mass (arrow); contrast-enhanced MRI sagittal subtraction image shows concordant mass (arrow).

Left to right: Subtraction right mediolateral oblique (MLO) CEM was non-diagnostic because of artifact, potentially due to motion misregistration from extended exposure time; subtraction right MLO implant displaced CEM image shows 5.8 cm enhancing mass (arrow); contrast-enhanced MRI sagittal subtraction image shows concordant mass (arrow).


March 18, 2021 — According to ARRS’ American Journal of Roentgenology (AJR), contrast-enhanced mammography (CEM) showed concordance with magnetic resonance imaging (MRI) in women with newly diagnosed breast cancer and breast augmentation.

Noting that CEM has not been investigated in women with breast augmentation, Molly Carnahan and her Mayo Clinic team in Phoenix, AZ, concluded, “the findings suggest a possible role of CEM for staging in women with breast augmentation and contraindication or limited access to MRI.”

From an institutional database of 2,215 women who underwent CEM between January 2015 and March 2020, the researchers identified breast implants in 67 women: 42 without corresponding MRI, 3 without breast cancer, 1 with axillary disease only, and 6 with neoadjuvant chemotherapy before CEM or MRI — leaving a final sample of 17 women (mean age 52 years; 6 with non-dense breasts, 11 with dense breasts).

The index cancer histology was invasive ductal carcinoma (IDC) in 15 (88%) women, invasive lobular carcinoma (ILC) in 1 (6%), and ductal carcinoma in situ in 1 (6%). Median index cancer size was 2 cm, and 2 (12%) index cancers were mammographically occult. Ultimately, CEM and MRI were concordant for the index cancer in all 17 women.

 

Six additional lesions were demonstrated by CEM and confirmed by MRI in 6 (35%) women: 3 multifocal, 1 multicentric, 2 contralateral. Two of these lesions revealed malignant histopathology: 1 IDC, 1 ILC.

“MRI did not identify any additional cancers not identified on CEM,” the authors of this AJR article added.

For more information: www.arrs.org


Related Content

News | Mammography

April 29, 2025 — iCAD, a global provider of clinically proven AI-powered cancer detection solutions, has announced a ...

Time April 29, 2025
arrow
News | Mammography

April 24, 2025 — GE HealthCare will feature its latest advancements in diagnostic accuracy and patient-centered breast ...

Time April 24, 2025
arrow
News | Breast Imaging

March 20, 2025 — GE HealthCare has launched Invenia Automated Breast Ultrasound (ABUS) Premium, the latest 3D ultrasound ...

Time March 21, 2025
arrow
News | Artificial Intelligence

March 10, 2025 — Lunit, a provider of AI-powered solutions for cancer diagnostics and therapeutics, has published a ...

Time March 10, 2025
arrow
News | Breast Imaging

March 04, 2025 — Optellum has entered a strategic agreement with Volpara Health, a Lunit company and a provider of ...

Time March 04, 2025
arrow
News | Artificial Intelligence

Feb. 19, 2025 — SimonMed Imaging and HeartLung Technologies have signed a strategic partnership to offer HeartLung's AI ...

Time March 04, 2025
arrow
News | Ultrasound Imaging

Jan. 28, 2025 — GE HealthCare recently announced it has received 510(k) clearance from the United States Food and Drug ...

Time January 29, 2025
arrow
News | Breast Imaging

Jan. 8, 2025 — ScreenPoint Medical has acquiredf Biomediq A/S, a research-based company focused on the research ...

Time January 10, 2025
arrow
News | Breast Imaging

Dec.11, 2024 — iCAD, Inc., a provider of clinically proven AI-powered cancer detection solutions, recently announced ...

Time December 18, 2024
arrow
News | Mammography

Dec. 5, 2024 — At RSNA 2024, Lunit and Volpara Health announced their unified vision, focusing on a comprehensive ...

Time December 05, 2024
arrow
Subscribe Now